Serina Therapeutics, Inc. Long-term Line of Credit
Serina Therapeutics, Inc. (SER) had Long-term Line of Credit of $9.69 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:LineOfCredit · last filed 2024-11-12
- 2024-09-30: Long-term Line of Credit $9.69M.
- 2022-12-31: Long-term Line of Credit $27.66M.
- 2022-09-30: Long-term Line of Credit $26.16M.
- 2021-12-31: Long-term Line of Credit $14.50M.
| Period end | Long-term Line of Credit |
|---|---|
| 2024-09-30 | $9.69M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $27.66M 10-K · filed 2023-03-31 |
| 2022-09-30 | $26.16M 10-Q · filed 2022-11-10 |
| 2021-12-31 | $14.50M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |